A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis

Phase 1

• Conditions: Moderately to Severely Active Ulcerative Colitis; MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856; Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

• Registration Number: EUCTR2018-004002-25-IT
• Lead Sponsor: JANSSEN CILAG INTERNATIONAL NV

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-17
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 950

Inclusion Criteria

1. Male or female, 18 years of age or older
2. Documented diagnosis of UC at least 3 months before screening
3. Moderately to severely active UC as defined by baseline modified Mayo score
4. History of inadequate response to or failure to tolerate conventional or advanced therapy as defined in the protocol
5. Screening laboratory test results within the study protocol defined parameters
Please see section 5.1 in the protocol for all inclusion criteria.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 875
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 75

Exclusion Criteria

1.Severe extensive colitis as defined in the study protocol
2.UC limited to the rectum only
3. Presence of a stoma
4. Presence or history of a fistula
5.Presence of symptomatic colonic or small bowel obstruction
6. History of extensive colonic resection
7.History of colonic mucosal dysplasia
8. Indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease.

Please see section 5.2 in the protocol for all exclusion criteria.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To evaluate the efficacy and safety of guselkumab in moderately to severely active UC.;Secondary Objective: •To evaluate the impact of guselkumab on health-related quality of life (HRQoL) and health economics outcome measures.<br>• To evaluate the PK, immunogenicity, and pharmacodynamics (PD) of guselkumab therapy, including changes in C-reactive protein (CRP) and fecal calprotectin.;Primary end point(s): 1. Induction study 1: Clinical response at Week 12<br>2. Induction study 2: Clinical remission at Week 12<br>3. Maintenance study1. Clinical remission at Week 44;Timepoint(s) of evaluation of this end point: point 1- 2 week 12<br>point 3 week 52

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Symptomatic remission at Week 44; Endoscopic healing at Week 44; Corticosteroid-free clinical remission at Week 44; Clinical response at Week 44; Histologic-endoscopic mucosal healing at Week 44; Clinical remission at Week 44among the participants who had achieved clinical remission at maintenance baseline; Endoscopic normalization at Week M-44;Timepoint(s) of evaluation of this end point: week 44; week 44; week 44; week 44; week 44; week 44; weeks 44